6th AGAH Dermatological Product Development Workshop Highlights

Posted:

July 2015

As a contributing sponsor Richmond Pharmacology recently attended the 6th AGAH Dermatological Product Development Workshop held June 23-24, 2015, in London, UK.

71 participants from 12 countries helped make this international workshop focused on bridging strategies from early development to regulatory approval a resounding success. The workshop featured an outstanding speaker panel of experts from industry, academics and the MHRA.Many of the current issues and challenges in the development of both innovative and generic topically applied drug products were addressed.Watch our latest video on our experience in dermatology studies

Back to news

More about us Adaptive Phase I, II & III Bridging Studies TQT Studies Patient Recruitment

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Latest Publications

View our latest peer-reviewed publications from a selection of our clinical trials.

Latest Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021

Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.

View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021

Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses.

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021

J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021

Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.